Restless Legs Syndrome Market to 2027, Future Outlook, COVID-19 Impact Analysis, Forecast 2021-2027

The restless leg syndrome (RLS) market is anticipated to exhibit a moderate CAGR of 6.0% during the forecast period. The exact cause of RLS is yet not know it is expected to occur due to chronic diseases such as diabetes, Parkinson's disease, kidney failure, or renal diseases. As per the Health and Safety Executive (HSE), in Great Britain, during the period (2018-2019), the total number of cases associated with work-related stress, depression, or anxiety was around 600,000, a prevalence rate of 1,800 per 100,000 workers. The number of new cases was 246,000, an incidence rate of 740 per 100,000 workers. The rising work-related stress that imparts due pressure on the nervous system is expected to be a major cause of RLS. Therefore, the high prevalence of work stress-related RLS is anticipated to create the demand for treatment of RLS using different drug devices, and therapy which in turn will drive the market growth.

A full report of Restless Legs Syndrome Market is available at: https://www.omrglobal.com/industry-reports/restless-legs-syndrome-market

The continuous contributions from the key players operating in the market are again making huge contributions to the global RLS Market. Pfizer, Inc., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Mylan N.V., Glenmark Pharmaceuticals Ltd., and so on are some of the key players contributing to the growth of the global RLS market. Some of the main strategies adopted by the players to cope with the competitive market and improve their role in the global RLS market are new product launches & innovations, alliances, agreements, and acquisitions.

For instance, in July 2019, Serina Therapeutics started developing a rotigotine formally known as SER-214, a dopamine agonist for the treatment of Restless Legs Syndrome (RLS). If the trial successful, it will significantly change the treatment landscape for patients as well as physicians across the globe. Additionally, in August 2019, Jazz Pharmaceuticals Inc. had acquired Cavion, Inc. This deal adds global rights for the future treatment of critical tremors to CX-8998, a T-type calcium channel modulator. Also, this acquisition represents an attractive opportunity for the company to broaden its sleep and neuroscience pipeline with expansion into movement disorders demonstrated proof-of-concept in phase 2 randomized, placebo-controlled trials.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/restless-legs-syndrome-market

Key Market Trends Covered in the Report

• Psychiatric reasons have been the major propellent factor for the market for ages.
• North America is anticipated to hold a major share global RLS market.
• Mergers & Acquisition, Product Launches, and partnerships: key strategies of players to thrive in the market.

Global Restless Leg Syndrome Market - Segmentation

By Treatment

• Medication
• Therapy
• Devices

By End-User

• Hospitals
• Homecare
• Others

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/restless-legs-syndrome-market

Restless Legs Syndrome Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• Akorn, Inc.
• Arbor Pharmaceuticals, LLC
• Boehringer Ingelheim GmbH
• GlaxoSmithKline plc
• Glenmark Pharmaceuticals Ltd.
• Jazz Pharmaceuticals plc
• Kyowa Hakko Kirin Co. Ltd.
• LGM Pharma
• Mallinckrodt Pharmaceuticals
• Merck Co, Inc.
• Mylan N.V.
• Pfizer, Inc.
• Serina Therapeutics, Inc.
• Teva Pharmaceutical Industries, Ltd.
• UCB S.A.

Reasons to Buying From us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.